Reversibly disulfide cross-linked micelles improve the pharmacokinetics and facilitate the targeted, on-demand delivery of doxorubicin in the treatment of B-cell lymphoma

Kai Xiao, Qiangqiang Liu, Nasir Al Awwad, Hongyong Zhang, Li Lai, Yan Luo, Joyce S Lee, Yuanpei Li, Kit Lam

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Doxorubicin (DOX) is commonly used to treat human malignancies, and its efficacy can be maximized by limiting the cardiac toxicity when combined with nanoparticles. Here, we reported a unique type of reversibly disulfide cross-linked micellar formulation of DOX (DOX-DCMs) for the targeted therapy of B-cell lymphoma. DOX-DCMs exhibited high drug loading capacity, optimal particle sizes (15-20 nm), outstanding stability in human plasma, and stimuli-responsive drug release profile under reductive conditions. DOX-DCMs significantly improved the pharmacokinetics of DOX, and its elimination half-life (t1/2) and area under curve (AUC) were 5.5 and 12.4 times of that of free DOX, respectively. Biodistribution studies showed that DOX-DCMs were able to preferentially accumulate in the tumor site and significantly reduce the cardiac uptake of DOX. In a xenograft model of human B-cell lymphoma, compared with the equivalent dose of free DOX and non-crosslinked counterpart, DOX-DCMs not only significantly inhibited the tumor growth and prolonged the survival rate, but also remarkably reduced DOX-associated cardiotoxicity. Furthermore, the exogenous administration of N-acetylcysteine (NAC) at 24 h further improved the therapeutic efficacy of DOX-DCMs, which provides a "proof-of-concept" for precise drug delivery on-demand, and may have great translational potential as future cancer nano-therapeutics.

Original languageEnglish (US)
Pages (from-to)8207-8216
Number of pages10
JournalNanoscale
Volume10
Issue number17
DOIs
StatePublished - May 7 2018

Fingerprint

Pharmacokinetics
Micelles
Disulfides
Doxorubicin
Tumors
Acetylcysteine
Cells
Plasma (human)
Drug delivery
Toxicity
Particle size
Nanoparticles
Heterografts
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Materials Science(all)

Cite this

Reversibly disulfide cross-linked micelles improve the pharmacokinetics and facilitate the targeted, on-demand delivery of doxorubicin in the treatment of B-cell lymphoma. / Xiao, Kai; Liu, Qiangqiang; Al Awwad, Nasir; Zhang, Hongyong; Lai, Li; Luo, Yan; Lee, Joyce S; Li, Yuanpei; Lam, Kit.

In: Nanoscale, Vol. 10, No. 17, 07.05.2018, p. 8207-8216.

Research output: Contribution to journalArticle

Xiao, Kai ; Liu, Qiangqiang ; Al Awwad, Nasir ; Zhang, Hongyong ; Lai, Li ; Luo, Yan ; Lee, Joyce S ; Li, Yuanpei ; Lam, Kit. / Reversibly disulfide cross-linked micelles improve the pharmacokinetics and facilitate the targeted, on-demand delivery of doxorubicin in the treatment of B-cell lymphoma. In: Nanoscale. 2018 ; Vol. 10, No. 17. pp. 8207-8216.
@article{e8653681e74647eda960e2f27c71e04d,
title = "Reversibly disulfide cross-linked micelles improve the pharmacokinetics and facilitate the targeted, on-demand delivery of doxorubicin in the treatment of B-cell lymphoma",
abstract = "Doxorubicin (DOX) is commonly used to treat human malignancies, and its efficacy can be maximized by limiting the cardiac toxicity when combined with nanoparticles. Here, we reported a unique type of reversibly disulfide cross-linked micellar formulation of DOX (DOX-DCMs) for the targeted therapy of B-cell lymphoma. DOX-DCMs exhibited high drug loading capacity, optimal particle sizes (15-20 nm), outstanding stability in human plasma, and stimuli-responsive drug release profile under reductive conditions. DOX-DCMs significantly improved the pharmacokinetics of DOX, and its elimination half-life (t1/2) and area under curve (AUC) were 5.5 and 12.4 times of that of free DOX, respectively. Biodistribution studies showed that DOX-DCMs were able to preferentially accumulate in the tumor site and significantly reduce the cardiac uptake of DOX. In a xenograft model of human B-cell lymphoma, compared with the equivalent dose of free DOX and non-crosslinked counterpart, DOX-DCMs not only significantly inhibited the tumor growth and prolonged the survival rate, but also remarkably reduced DOX-associated cardiotoxicity. Furthermore, the exogenous administration of N-acetylcysteine (NAC) at 24 h further improved the therapeutic efficacy of DOX-DCMs, which provides a {"}proof-of-concept{"} for precise drug delivery on-demand, and may have great translational potential as future cancer nano-therapeutics.",
author = "Kai Xiao and Qiangqiang Liu and {Al Awwad}, Nasir and Hongyong Zhang and Li Lai and Yan Luo and Lee, {Joyce S} and Yuanpei Li and Kit Lam",
year = "2018",
month = "5",
day = "7",
doi = "10.1039/c8nr00680f",
language = "English (US)",
volume = "10",
pages = "8207--8216",
journal = "Nanoscale",
issn = "2040-3364",
publisher = "Royal Society of Chemistry",
number = "17",

}

TY - JOUR

T1 - Reversibly disulfide cross-linked micelles improve the pharmacokinetics and facilitate the targeted, on-demand delivery of doxorubicin in the treatment of B-cell lymphoma

AU - Xiao, Kai

AU - Liu, Qiangqiang

AU - Al Awwad, Nasir

AU - Zhang, Hongyong

AU - Lai, Li

AU - Luo, Yan

AU - Lee, Joyce S

AU - Li, Yuanpei

AU - Lam, Kit

PY - 2018/5/7

Y1 - 2018/5/7

N2 - Doxorubicin (DOX) is commonly used to treat human malignancies, and its efficacy can be maximized by limiting the cardiac toxicity when combined with nanoparticles. Here, we reported a unique type of reversibly disulfide cross-linked micellar formulation of DOX (DOX-DCMs) for the targeted therapy of B-cell lymphoma. DOX-DCMs exhibited high drug loading capacity, optimal particle sizes (15-20 nm), outstanding stability in human plasma, and stimuli-responsive drug release profile under reductive conditions. DOX-DCMs significantly improved the pharmacokinetics of DOX, and its elimination half-life (t1/2) and area under curve (AUC) were 5.5 and 12.4 times of that of free DOX, respectively. Biodistribution studies showed that DOX-DCMs were able to preferentially accumulate in the tumor site and significantly reduce the cardiac uptake of DOX. In a xenograft model of human B-cell lymphoma, compared with the equivalent dose of free DOX and non-crosslinked counterpart, DOX-DCMs not only significantly inhibited the tumor growth and prolonged the survival rate, but also remarkably reduced DOX-associated cardiotoxicity. Furthermore, the exogenous administration of N-acetylcysteine (NAC) at 24 h further improved the therapeutic efficacy of DOX-DCMs, which provides a "proof-of-concept" for precise drug delivery on-demand, and may have great translational potential as future cancer nano-therapeutics.

AB - Doxorubicin (DOX) is commonly used to treat human malignancies, and its efficacy can be maximized by limiting the cardiac toxicity when combined with nanoparticles. Here, we reported a unique type of reversibly disulfide cross-linked micellar formulation of DOX (DOX-DCMs) for the targeted therapy of B-cell lymphoma. DOX-DCMs exhibited high drug loading capacity, optimal particle sizes (15-20 nm), outstanding stability in human plasma, and stimuli-responsive drug release profile under reductive conditions. DOX-DCMs significantly improved the pharmacokinetics of DOX, and its elimination half-life (t1/2) and area under curve (AUC) were 5.5 and 12.4 times of that of free DOX, respectively. Biodistribution studies showed that DOX-DCMs were able to preferentially accumulate in the tumor site and significantly reduce the cardiac uptake of DOX. In a xenograft model of human B-cell lymphoma, compared with the equivalent dose of free DOX and non-crosslinked counterpart, DOX-DCMs not only significantly inhibited the tumor growth and prolonged the survival rate, but also remarkably reduced DOX-associated cardiotoxicity. Furthermore, the exogenous administration of N-acetylcysteine (NAC) at 24 h further improved the therapeutic efficacy of DOX-DCMs, which provides a "proof-of-concept" for precise drug delivery on-demand, and may have great translational potential as future cancer nano-therapeutics.

UR - http://www.scopus.com/inward/record.url?scp=85046676437&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85046676437&partnerID=8YFLogxK

U2 - 10.1039/c8nr00680f

DO - 10.1039/c8nr00680f

M3 - Article

C2 - 29682647

AN - SCOPUS:85046676437

VL - 10

SP - 8207

EP - 8216

JO - Nanoscale

JF - Nanoscale

SN - 2040-3364

IS - 17

ER -